Literature DB >> 34647038

A protocol for rapid and parallel isolation of myocytes and non-myocytes from multiple mouse hearts.

Gabriella E Farrugia1, Micheal A McLellan2,3, Kate L Weeks1,4,5, Aya Matsumoto1, Charles D Cohen1,6, Crisdion Krstevski1,6, Taylah L Gaynor1,6, Adam C Parslow1,5, Julie R McMullen1,4,6,7,8, Alexander R Pinto1,6,8.   

Abstract

This protocol features parallel isolation of myocytes and non-myocytes from murine hearts. It was designed with considerations for (1) time required to extract cardiac cells, (2) cell viability, and (3) protocol scalability. Here, a peristaltic pump and 3D-printed elements are combined to perfuse the heart with enzymes to dissociate cells. Myocytes and non-myocytes extracted using this protocol are separated by centrifugation and/or fluorescence-activated cell sorting for use in downstream applications including single-cell omics or other bio-molecular analyses. For complete details on the use and execution of this protocol, please refer to McLellan et al. (2020).
© 2021 The Author(s).

Entities:  

Keywords:  Cell Biology; Cell isolation; Cell separation/fractionation

Mesh:

Year:  2021        PMID: 34647038      PMCID: PMC8496295          DOI: 10.1016/j.xpro.2021.100866

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

The protocol below describes the methodology for parallel isolation of both cardiomyocytes and non-myocytes from four adult mouse hearts and innovates upon the approach by Ackers-Johnson et al. (2016). We have routinely applied this protocol on mice aged 8–20 weeks and anticipate it can be readily used to process hearts from younger or older mice if the hearts can be isolated and clamped as described below. Further, while the protocol describes the processing of four hearts, the approach can be scaled to isolate cells from fewer or more hearts (e.g., 2–16 hearts). Note, the parallel processing of a larger number of hearts may require more technicians to aid in heart dissection and monitoring of the cell dissociation system.

Preparation prior to day of experiment

Timing: 2–4 h Prepare all stocks, buffers and solutions listed under in the Buffers and stocks required table (below). In this protocol we demonstrate simultaneous perfusion and digestion of four hearts. As aforementioned, the setup can be easily modified to process different numbers of hearts. However, an even number of hearts is recommended to maintain equal fluidic pressure. If required, autoclave dissection tools. If required, print magnetic hemostat holders (Figure 1A, vii) and assemble perfusion platform (see Figures 1A–1G). The STL file required for printing the magnetic hemostat holder is downloadable in the Pinto Laboratory Github repository (https://github.com/pinto-lab/Farrugia-et-al_2021-magnetic-hemostat-holder).
Figure 1

Assembly of 3D-printed perfusion platform

(A) Collection of all required elements. Image shows: (i) superglue; (ii) 3-way stop-cock; (iii) LS-13 nylon tubing; (iv) 23½ gauge needle with beveled tip removed and needle tip filed; (v) Tygon tubing; (vi) male luer to hose barb adapter fitting; (vii) 3D-printed perfusion platform; (viii) neodymium magnets; (ix) solid-core 22AWG electrical wire. Steel baking tray is also shown (but not labeled).

(B) Assembly of components before insertion of magnets. Note: LS-13 tubing is used as an intermediate tubing to couple the adapter fitting (component vi) and the narrow Tygon tubing.

(C) Mounting of magnet to the top of the platform. Note: a small amount of superglue is applied to the plastic seat which will house the magnet.

(D) Insertion of magnets to the bottom of the platform. Note: a small amount of superglue is applied to the holes which house the magnets.

(E) Fully assembled platform with 30G needle (orange) attached.

(F) Setup of fluidics system for processing of four hearts.

(G) Example image of perfusion system processing four hearts.

(H) Example image of a heart being processed that is not completely digested.

(I) Example image of a heart being processed, that is completely digested and ready to be removed from platforms.

Assembly of 3D-printed perfusion platform (A) Collection of all required elements. Image shows: (i) superglue; (ii) 3-way stop-cock; (iii) LS-13 nylon tubing; (iv) 23½ gauge needle with beveled tip removed and needle tip filed; (v) Tygon tubing; (vi) male luer to hose barb adapter fitting; (vii) 3D-printed perfusion platform; (viii) neodymium magnets; (ix) solid-core 22AWG electrical wire. Steel baking tray is also shown (but not labeled). (B) Assembly of components before insertion of magnets. Note: LS-13 tubing is used as an intermediate tubing to couple the adapter fitting (component vi) and the narrow Tygon tubing. (C) Mounting of magnet to the top of the platform. Note: a small amount of superglue is applied to the plastic seat which will house the magnet. (D) Insertion of magnets to the bottom of the platform. Note: a small amount of superglue is applied to the holes which house the magnets. (E) Fully assembled platform with 30G needle (orange) attached. (F) Setup of fluidics system for processing of four hearts. (G) Example image of perfusion system processing four hearts. (H) Example image of a heart being processed that is not completely digested. (I) Example image of a heart being processed, that is completely digested and ready to be removed from platforms. Cut 177 μm nylon mesh to appropriately cover 50 mL tube openings. Mesh with different pore size could be used (for example 250 μm). 177 μm pore diameter mesh used here readily permits passage of cardiomyocytes and other cells while excluding undigested tissue.

Preparation on day of experiment

Timing: 1–2 h Optional for cardiomyocyte cell culture: In sterile conditions, add laminin to 15 μg/mL to the required volume of PBS without Ca2+ Mg2+. Coat 60 mm tissue culture dish with 2 mL of 15 μg/mL laminin in sterile PBS without Ca2+ Mg2+. Incubate at 37°C, 5% CO2 for at least 1 h prior to plating cardiomyocytes. For plating, one heart will require two 60 mm tissue culture dishes. Alternatively, one 100 mm tissue culture dish can be used per heart. If so, use 3 mL of 15 μg/mL laminin in sterile PBS without Ca2+ Mg2+ for coating. The laminin coated tissue culture dishes should be prepared on the day of the experiment and allowed to incubate with laminin at least 1 hour prior to use to allow adhesion of laminin. The laminin solution can be left in the dish for several hours during the day however not overnight. Once used, laminin coated tissue culture dishes should be discarded. Place on ice 10 mL syringes loaded with 7 mL of ice-cold EDTA Buffer with 25G hypodermic needles attached. Prepare heparin solution to a final concentration of 1 U/μL in PBS without Ca2+ Mg2+. Administer 100 μL of heparin solution to each mouse by intraperitoneal injection. Allow 15–30 min for adequate absorption of heparin. While waiting for heparin to take effect (step 7): Pre-chill the swing-bucket centrifuge and required accessories (buckets and tube holders) to 4°C. Alternatively, if the primary objective is to isolate cardiomyocytes for tissue culture, leave a swing-bucket centrifuge at room temperature (RT). Pre-heat the water bath to 37°C and place the bottle containing EDTA buffer in the water bath (after loading 10 mL syringes with 7 mL cold EDTA buffer in step 6 above). Setup fluidic system as shown in Figures 1F–1G. Prime tubing and needles for perfusion with EDTA buffer by running solution through the tubing to expel any trapped air. While priming, ensure there are no leaks from fixtures and fluidics. Attend to any leaks as this will affect the efficiency of perfusion of the hearts, cell isolation and viability. It is prudent to have spare fluidic fixture components available in case replacement of a broken element is required. For further considerations regarding fluidic setup preparation see problem 2 in the troubleshooting section for more details. Prepare: Perfusion Buffer with enzymes and leave at RT. Stop Buffer and keep on ice throughout protocol. Leave at RT if cardiomyocytes are to be cultured.

Key resources table

Materials and equipment

Prepare prior to the day of the experiment

100 × collagenases II and IV Reconstitute both collagenases in ddH2O. Filter sterilize through 0.22 μm and store in 1 mL aliquots in -80°C. Stable for up to 6 months. 1000 × protease XIV Reconstitute in ddH2O. Filter sterilize through 0.22 μm and store in 200 μL aliquots in -80°C. Stable for up to 6 months. EDTA buffer Prepare 50 mL per heart. Prepare required volume of solution in ddH2O with a final pH of 7.8. Filter sterilize through 0.22 μm and protect from light. Store at 4°C for up to 1 week. Perfusion buffer Prepare 60 mL per heart. Prepare required volume of solution in MQH2O with a final pH of 7.8. Filter sterilize through 0.22 μm and protect from light. Store at 4°C for up to 1 week. Wash buffer Prepare 10 mL per heart. Keep sterile and store at 4°C until experiment day. Can be made on or prior to experiment day. 10 × ACM Prepare in 80 mL MQH2O (final volume 100 mL). Adjust pH to 7.25 with 1M NaOH, taking note of volume required. Add NaCl calculated by the following equation: NaCl to add (g) = -0.0585 × (volume of NaOH added) + 6.02 Make up to 100 mL with MQH2O. Filter sterilize through 0.22 μm. Can be prepared 3–4 days in advance and stored at 4°C.

Prepare on day of the experiment, before you begin.

Perfusion buffer with enzymes Prepare from cold reagents 40 mL per heart on day of experiment and allow to warm to room temperature. Stop buffer Prepare 20 mL per heart on day of experiment. Keep Stop buffer on ice for cells with downstream applications requiring maintaining a cold temperature. Keep Stop buffer at RT for myocytes destined for cell culture. ACMBICT Prepare 50 mL per heart. Keep at RT ACMBICT/FCS Prepare 30 mL per heart. Keep at RT Modified MEM Prepare 30 mL per heart. Keep at RT Myocyte wash buffer 1 Prepare 10 mL per heart and store at RT until use. Myocyte wash buffer 2 Prepare 8 mL per heart and store at RT until use. Myocyte wash buffer 3 Prepare 10 mL per heart and store at RT until use. Plating media Prepare 20 mL per heart. Incubate at 37°C, 5% CO2 with loosened cap until use. Maintenance media Prepare 20 mL per heart and filter sterilize. Incubate at 37°C, 5% CO2 with loosened cap until use.

Step-by-step method details

Preparation of hearts for enzymatic digestion via perfusion

Timing: 0.5–1 h If possible, we recommend three investigators participate in this initial step of the protocol—two dissecting tissue and one handling the perfusion platform. The number of investigators is dependent on the competence and speed of technicians and the number of hearts being processed. For a detailed description of thoracotomy and externalization of the mouse heart, see Pinto et al. (2013). Euthanize four mice by CO2 asphyxiation and promptly pin in supine position—two per dissection board per investigator. Place freshly prepared Perfusion buffer with enzymes in 37°C water bath. Alternatively, euthanasia can be performed by administration of ethical and pharmaceutically-appropriate drugs. Euthanasia by cervical dislocation is NOT recommended as an intact circulatory system is desired. CRITICAL: During dissection, outlined in steps (steps 3–8), take care not to pierce any organs, especially the heart. Spray anterior thorax with 80% v/v ethanol solution to minimize fur dispersal. Cut away a small 1–2 cm2 area of skin above the intersection of the septum and diaphragm. While holding the septum with forceps, slowly raise the ribcage and carefully make an incision in the abdominal cavity with surgical scissors, taking care to follow the lateral margins of the rib cage. Septum is held with forceps from steps 4–7. While still holding the septum, if required, gently push away any exposed abdominal organs to reveal diaphragm. This can be achieved by closing the scissors (to minimize risk of damaging organs) and using them to push aside organs. While exposing the inferior cavity of the diaphragm, cut the diaphragm along the margin of where the diaphragm and rib cage intersect. With care and without damaging the lungs; cut the ribcage upwards towards the arms from the left- and right-hand side. Pin the ribcage back adjacent to the left ear of the mouse and carefully remove the pericardium (if visible) from the heart gently. Perform steps 2–8 per mouse on dissection board first. Follow the next steps (9–14) in this section 1 mouse at a time per scientist. Steps 9–14 typically requires <5 mins. Locate and cut the inferior vena cava and immediately perfuse the animal with 7 mL of ice-cold EDTA buffer in the pre-loaded syringes, through the right ventricle. Place forceps below the heart and gently raise it, elevating it from other organs to expose the aorta. Using a curved hemostat, clamp the aorta and secure firmly, taking care not to clamp the atria. For troubleshooting regarding atria clamping see troubleshooting section, problem 3. With the heart clamped, cut below the hemostat to isolate each mouse heart, and transfer the clamped heart to the perfusion platform. Magnetically secure the hemostat in place, with the ventricles pointing upward and place a 30G needle in the apex of the left ventricle (as shown in Figures 1G–1I). If difficulties are experienced in maintaining needle position, refer to problem 1 in troubleshooting. Start perfusion using the peristaltic pump at a rate of 1 mL/min/heart with EDTA buffer at 37°C and proceed from step 9 with the next heart. Ensure a waste reservoir is placed beneath the perfusing hearts to collect perfusate. All perfusate (here and in subsequent steps) is collected in a waste reservoir beneath the hearts. As the waste reservoir fills, use a Pasteur pipette to periodically empty the contents into a waste beaker. During perfusion, ensure the surface of hearts remain moist by periodically basting the hearts using a Pasteur pipette with clean pre-warmed EDTA buffer. It is important to prevent tissue from drying out. Once all hearts are being simultaneously perfused with EDTA buffer, increase perfusion flow rate to 6 mL/min (1.25 mL/min/heart). TIP: When processing more than four hearts, multiple fluidic channels (Figure 1F) can be used to process hearts in batches of four. Alternatively, individual fluidic channels can be closed using the stopcocks to process fewer hearts.

Enzymatic digestion and cell isolation

Timing: 1–2 h Observation: As EDTA buffer is perfusing through the heart, perfusate with blood will emerge from the heart. The perfusate will progressively clear as blood is removed from the tissue. After blood is no longer dripping into the waste reservoir (∼5 min after start of EDTA buffer perfusion), pause the peristaltic pump and switch buffers from EDTA buffer to Perfusion buffer with enzymes (which should be in the 37°C water bath – step 1) before resuming perfusion at 6 mL/min (1.25 mL/min/heart). During digestion: Baste hearts undergoing perfusion with the same pre-warmed Perfusion buffer with enzymes (at 37°C) until it appears slightly blanched, translucent, and dilated (∼30 min). We have observed shorter perfusion times when agents such as sodium pentobarbitone are used for euthanasia. If uneven rates of digestion are observed, see problem 4 in troubleshooting section. Further, as the hearts perfuse, the perfusate is accumulating in the waste reservoir – this is to be discarded. While waiting for hearts to digest, prepare the following per heart for the next steps and leave at RT: A 30 mm petri dish with 1 mL of Perfusion buffer with enzymes. A 50 mL tube with 2 mL of Perfusion buffer with enzymes. When digestion is complete (Figures 1H and 1I), hold the prepared 30 mm petri dish with buffer below the heart. Remove hypodermic needle from the heart. Indicating a well-digested heart, the tissue will appear soft. Ensuring the heart is held over the petri-dish (present at RT, prepared step – 18b.i), using the curved scissors, cut between the atria and the ventricles to collect the cardiac ventricles in the petri dish. Repeat for remaining hearts. At ambient temperature, gently pull apart the tissue within each petri dish using forceps to release the cells and break up the tissue so that it may be aspirated by a 3 mL Pasteur pipette. If heart appears incompletely digested, refer to the troubleshooting section, problem 5. Using a 3 mL sterile Pasteur pipette, transfer the suspension into the 50 mL tube with RT Perfusion buffer and triturate gently 10 times using the same pipette. Place 50 mL tube in the 37°C water bath with caps loosely tightened for 5 min, and afterward pipette mix as aforementioned using a Pasteur pipette 15 times. If the objective of this protocol is to proceed with cell culture of cardiomyocytes, please follow alternative steps 31–37 “Alternative steps when isolating myocytes for cell culture” (instead of steps 24–30, which are primarily for isolation of non-myocytes). The alternative steps prevent the exposure of cardiomyocytes to low temperatures and help preserve their physiological characteristics. The key differences of the alternative steps are the temperatures at which cells are maintained. If downstream processing of cardiomyocytes requires preservation of nucleic acids, protein and other elements that are labile at RT, then we recommend steps 24–30. We routinely use the steps at lower temperature for isolation of cardiomyocyte nuclei for RNA sequencing. Place the 50 mL tube back in the 37°C water bath and incubate for another 5 min. During the incubation period, aliquot 5 mL of cold Stop buffer to a fresh 50 mL tube per heart and place on ice. After incubation, gently pipette-mix the cardiac cell suspension using a Pasteur pipette for another 15 times. Filter the cell suspension through 177 μm nylon mesh into the pre-prepared 50 mL tube containing Stop buffer and leave on ice, undisturbed, for 10 min.

Separation of myocytes from non-myocytes

Timing: 0.5–1 h In this final step of the protocol, non-myocytes are separated from myocytes and prepared for down-stream applications. Centrifuge the cell suspensions at 50×g for 2 min at 4°C (with centrifuge breaks activated). Prepare 15 mL tubes with 7 mL of cold wash buffer per heart and place on ice. After centrifugation place tubes on ice. A loose pellet (primarily cardiomyocytes) and cloudy supernatant (primarily non-myocytes) will be present. Supernatant – non-myocytes: Transfer all but approximately 1 mL of supernatant to the 15 mL tubes (step 28) through 70 μm nylon mesh into the wash buffer and place on ice. Retain 50 mL tube for processing cardiomyocytes (step 29b, below). Top-up the volume of non-myocyte enriched samples to 15 mL with cold wash buffer and subsequently centrifuge at 200×g for 15 min at 4°C, with centrifuge breaks deactivated. Remove the supernatant and re-suspend the pellet (containing non-myocytes) in a desired buffer depending on subsequent application. Pellet – Cardiomyocytes: Add 5 mL of cold Stop buffer to the cardiomyocyte pellet in the 50 mL tube (after removing supernatant) and gently re-suspend the pellet. Spin down cardiomyocytes an additional time at 50×g for 2 min at 4°C (with centrifuge breaks activated). Aspirate supernatant and re-suspend pellet in desired buffer. Steps i and ii of step 29b may be repeated to decrease presence of non-myocytes Use isolated myocytes or non-myocytes in desired application.

Alternative steps when isolating myocytes for cell culture

Follow steps 31–37 when preparing cardiomyocytes for cell culture to minimize stress cardiomyocytes may experience due to rapid changes in temperature and preserve their physiological characteristics. Note, the non-myocyte fraction is preserved either way. Place the 50 mL tube back in the 37°C water bath and incubate for another 5 min. During the incubation period, aliquot 5 mL of RT Stop buffer to a fresh 50 mL tube per heart and leave at RT After incubation, gently pipette-mix the cardiac cell suspension using a Pasteur pipette another 15 times. Filter the cell suspension through 177 μm nylon mesh into the pre-prepared 50 mL tube containing Stop buffer and at RT, undisturbed, for 10 min.

Separation of myocytes from non-myocytes (for cell culture)

Timing: 0.5–1 h In this final step of the protocol, non-myocytes are separated from myocytes and prepared for down-stream applications. Centrifuge the cell suspensions at 50×g for 2 min at RT (with centrifuge breaks activated). Prepare 15 mL tubes with 7 mL of cold wash buffer per heart and place on ice. After centrifugation place tubes on ice. A loose pellet (primarily cardiomyocytes) and cloudy supernatant (primarily non-myocytes) will be present. Supernatant – non-myocytes: Transfer all but approximately 1 mL of supernatant to the 15 mL tubes (step 35) through 70 μm nylon mesh into the wash buffer and place on ice. Retain 50 mL tube for processing cardiomyocytes (step 36b, below). Top-up the volume of non-myocyte enriched samples to 15 mL with cold wash buffer and subsequently centrifuge at 200×g for 15 min at 4°C, with centrifuge breaks deactivated. Remove the supernatant and re-suspend the pellet (containing non-myocytes) in a desired buffer depending on subsequent application. Pellet – Cardiomyocytes: Add 10 mL of RT Stop buffer to the cardiomyocyte pellet in the 50 mL tube (after removing supernatant) and gently re-suspend the pellet at RT Spin down cardiomyocytes an additional time at 20×g for 3 min at RT (with centrifuge breaks activated). Aspirate supernatant and re-suspend in desired buffer. Use isolated myocytes or non-myocytes in desired application.

Optional step: Preparation of myocytes for cell culture with Ca2+ reintroduction

If cardiomyocytes are to be used for applications such as cell culture, the following protocol is recommended to gradually restore physiological calcium levels prior to plating. The myocytes are sequentially incubated in Myocyte Wash Buffers containing increasing concentration of Ca2+ of 0.18, 0.45 and 1.08 mM (Myocyte Wash Buffer 1, 2 and 3, respectively) and are plated in Plating Media containing 1.26 mM Ca2+. Cardiomyocytes are fragile. Avoid shocks/vibrations and pipette gently during cell resuspension steps. Further, handle tubes with care after centrifugation as the cardiomyocytes are loosely pelleted. At step 36(b)iii, resuspend cardiomyocytes in 10 mL Myocyte Wash Buffer 1. Transfer cell suspension to a 70 mL specimen jar (to reduce cell clumping and to avoid ischemia) and incubate at RT for 10 min. Post incubation, transfer cells to a 14 mL round-bottomed tube and centrifuge at 20×g for 3 min at RT Aspirate supernatant, leaving a small volume, ∼(50–100 μL) so as not to disturb the pellet, and resuspend cardiomyocytes in 8 mL Myocyte Wash Buffer 2, transfer to a 70 mL specimen jar and incubate at RT for 10 min. Transfer cells to a 14 mL round-bottomed tube and centrifuge at 20×g for 3 min at RT Aspirate supernatant, leaving a small volume (∼50–100 μL) so as not to disturb the pellet, and resuspend cardiomyocytes in 10 mL Myocyte Wash Buffer 3, transfer to a 70 mL specimen jar and incubate at RT for 10 min. Transfer cells to a 14 mL round-bottomed tube and centrifuge at 20×g for 3 min at RT Aspirate supernatant and gently resuspend cardiomyocytes in desired volume of Plating media (e.g., 5 mL for a 60 mm tissue culture dish). Immediately aspirate laminin from cell culture plates, wash with sterile PBS without Ca2+ Mg2+ and gently add cardiomyocytes in Plating Media to dish. Incubate plates at 37°C, 5% CO2 for 1 h to allow cells to adhere. After 1 h, replace Plating Media with Maintenance Media and incubate cells at 37°C, 5% CO2 for an additional 1.5–2 h prior to performing any treatments (e.g., stimulation with agonists for signaling studies).

Expected outcomes

Using this protocol, both myocytes and non-myocytes can be successfully isolated from multiple hearts in parallel. Isolated cardiomyocytes generally exhibit typical morphology with preserved sarcomeric organization (Figure 2A) and a yield of ∼90,000 adherent cardiomyocytes can be attained per heart (Table 1). While we have not completed physiological assessment of isolated cardiomyocytes, we have cultured these cells up to 48 h with best morphology observed at 24 h or less (Figure 2B). However, this protocol innovates upon other published work (Ackers-Johnson et al., 2016) which comprehensively characterizes the physiological characteristics of cardiomyocytes isolated using buffers and general approach described here.
Figure 2

Expected outcomes

(A) An example image of healthy cardiomyocytes isolated using the perfusion system. Left panel, phase contrast images showing rod shaped cardiomyocytes. Image taken after Ca2+ reintroduction steps, plating onto a laminin coated dish, and media change. Scale bar indicates 200 μm. Center panel, confocal micrograph of adherent cardiomyocytes stained with Calcein Green. Scale bar indicates 20 μm. Right panel, zoomed image (insert from center panel) shows striations and sarcomeric organization within cardiomyocytes.

(B) Phase contrast images of adherent cardiomyocytes, captured at varying intervals from plating (0 h) to 2 days (48 h) in culture. Insert images (bottom row; arrows in middle row indicate insert positions) show sarcomeric organization of cultured cardiomyocytes. Scale bars indicate 200 μm.

(C) Flow cytometric analysis of non-myocytes isolated using the perfusion system. Gating strategy shows the determination of nucleated and viable single-cells and major non-myocyte cell classes (ECs, endothelial cells; RMCs, resident mesenchymal cells; Leuks, leukocytes).

(D) Quantification of the proportion of major non-myocyte cell classes determined using flow cytometry (n= 16). Error bars indicate standard deviation from the mean.

Table 1

Cardiomyocyte and non-myocyte yields per heart

Cell typeCell count
Non-myocytes/heart determined by flow cytometrya2,000,000
Cardiomyocytes (adherent cells in culture) per heart90,000

All counts are equated to the nearest 10,000.

Average count of 16 hearts of 14 week old animals; this number excludes cells that are not captured by the gates shown in Figure 2C.

Expected outcomes (A) An example image of healthy cardiomyocytes isolated using the perfusion system. Left panel, phase contrast images showing rod shaped cardiomyocytes. Image taken after Ca2+ reintroduction steps, plating onto a laminin coated dish, and media change. Scale bar indicates 200 μm. Center panel, confocal micrograph of adherent cardiomyocytes stained with Calcein Green. Scale bar indicates 20 μm. Right panel, zoomed image (insert from center panel) shows striations and sarcomeric organization within cardiomyocytes. (B) Phase contrast images of adherent cardiomyocytes, captured at varying intervals from plating (0 h) to 2 days (48 h) in culture. Insert images (bottom row; arrows in middle row indicate insert positions) show sarcomeric organization of cultured cardiomyocytes. Scale bars indicate 200 μm. (C) Flow cytometric analysis of non-myocytes isolated using the perfusion system. Gating strategy shows the determination of nucleated and viable single-cells and major non-myocyte cell classes (ECs, endothelial cells; RMCs, resident mesenchymal cells; Leuks, leukocytes). (D) Quantification of the proportion of major non-myocyte cell classes determined using flow cytometry (n= 16). Error bars indicate standard deviation from the mean. Cardiomyocyte and non-myocyte yields per heart All counts are equated to the nearest 10,000. Average count of 16 hearts of 14 week old animals; this number excludes cells that are not captured by the gates shown in Figure 2C. Using flow cytometry, we determine approximately 2 million non-myocytes can be extracted per heart (Table 1). It should be noted here; we use stringent criteria to calculate the yield of non-myocytes. This includes singlet-gating and viability dyes to exclude cell doublets and nucleated dead cells. We also used Vybrant™ DyeCycle™ and Calcein Blue dyes to ensure we only count nucleated and metabolically active cells, respectively (Pinto et al., 2016). Moreover, all three major cell classes of non-myocytes can be effectively isolated (Figures 2C and 2D). The major non-myocyte cell types are endothelial cells (ECs; both lymphatic and vascular), leukocytes (Leuks; granulocytes, myeloid and non-myeloid cells) and resident mesenchymal cells (RMCs; fibroblasts and mural cells). However, we find the proportion of endothelial cells are generally lower than in alternative protocols (Pinto et al., 2016; Squiers et al., 2020) where more mechanically rigorous methods are applied to disaggregate the dense vasculature of the heart (Table 2). However, as endothelial cells are abundant in the heart, this does not limit subsequent studies which require endothelial cells. Further, the parallel non-myocyte and cardiomyocyte isolation methodology described here performs better overall compared to widely used commercial protocols.
Table 2

Non-myocyte comparison yield per heart determined by flow cytometry

Non-myocyte cell typeThis protocolAlternate protocol (Pinto et al., 2016; Squiers et al., 202)Proprietary Miltenyi Biotec Multi Tissue Dissociation Kit 2 and gentleMACS™ Octo Dissociatorb
Endothelial cells, ECsa1,200,0004,100,000200,000
Resident mesenchymal cells, RMCsa500,0001,200,000390,000
Leukocytes, Leuksa400,000420,000610,000

All counts are averaged from 16 hearts from 14 week old animals and equated to the nearest 10,000

Following manufacturer’s protocol.

Non-myocyte comparison yield per heart determined by flow cytometry All counts are averaged from 16 hearts from 14 week old animals and equated to the nearest 10,000 Following manufacturer’s protocol.

Limitations

Variability of results depending on ambient temperature: Temperature during perfusion (step 18.a) of the hearts with Perfusion buffer with enzymes is optimal at 37°C. Although the buffer was kept in a 37°C-set water bath, we recorded the hearts’ surface temperature at ∼18°C. Although colder than expected, we were still able to isolate cardiomyocytes and non-myocytes. In laboratories with warmer ambient temperatures, we have successfully isolated both myocyte and non-myocytes in 15 min of perfusion. Inability to weigh ventricles before dissociation: Due to the necessity to keep atria and base of the ascending aorta intact to facilitate perfusion of buffers and enzymes through the coronary vasculature, the ventricles cannot be precisely weighed. This may be problematic for studies which aim to measure heart mass to determine hypertrophy. Variability of results depending on the investigator: We have observed that some differences in cellular composition may arise from different scientists performing the protocols. If consistency is required, we recommend that the same investigators perform the same tasks of the protocol. Despite this limitation, in preparing this report, investigators from an independent laboratory were able to successfully follow the protocol described. 3D printed components: While we have provided CAD generated files for 3D printing perfusion platforms, we recognize that 3D printers may not be available to all researchers. In this event, we recommend you contact a local 3D printing service which are now widely available.

Troubleshooting

Problem 1

Inserting hypodermic needle into heart ventricle and maintaining needle position above the ventricle while perfusing the heart It is sometimes difficult to align the hypodermic needle attached to the platform with a heart ventricle (clamped by a hemostat). It may be also challenging to maintain the needle position, while the heart is being perfused. This is primarily due to the electrical wire (attached to the tube holding the hypodermic needle) which may change position after needle insertion.

Potential solution

At the final stage of setting-up the perfusion platforms, pre-align the hypodermic needle to the approximate position a heart would be using the curved hemostat placed on the perfusion platform as a guide. After commencing the protocol and placing the clamped heart on the perfusion platform, the needle can be easily inserted and its position stably maintained. If the position or angle of the heart requires to be altered, gently move the hemostat. Moving the hemostat allows two dimensions of adjustment to ensure the needle position is directly above the heart.

Problem 2

Temperature control Keeping ambient air temperature consistent around the hearts being perfused may be challenging and potentially affect enzyme activity. This may be a significant issue in areas such as those adjacent to high traffic walkways, doors or ventilations ports. Setup perfusion workspace in an area that is not likely to experience temperature or air movement fluctuations. Alternatively, consider placing an acrylic (Perspex) enclosure around the back and sides of the perfusion platform.

Problem 3

Accidental clamping of atria When clamping the heart after cold EDTA buffer perfusion through the right ventricle, the atria may be clamped as well. If atria are accidentally clamped with the hemostat, do not discard this heart. Continue with the protocol and avoid removing the hemostat at attempting to re-clamp the heart as this could potential damage the heart tissue further. We have found that this protocol can be forgiving without impacting cell yield or viability.

Problem 4

Uneven rate of digestion in multiple hearts During digestion with Perfusion buffer some hearts may appear better digested than others. This could be due to multiple reasons including (1) experimental treatments to hearts may have been present – for example, hearts with significant presence of fibrosis may require longer perfusion times. (2) Issues relating to the perfusion platform. If the perfusion discrepancies are associated with the platform follow the below steps to ensure that the fluidic system is set up and operating correctly: - i. Pause the pump. ii. Ensure that the aspirating tube is placed within the buffer being perfused iii. Ensure that there are no leaks from tubing or fixtures, and tighten or replace tubing and fixtures as necessary. iv. Ensure the 30G needle placed at the apex of the hearts is positioned well and expelling fluid in the left ventricular chamber v. Resume flow of buffer and perfusion.

Problem 5

Undigested heart after perfusion A heart that is incompletely digested will be more rigid than the soft and delicate hearts that are completely digested. While the ability to extract large quantities of cells may be limited if the heart is incompletely digested, proceed with the protocol as described above since cells can still be extracted from the heart. If the tissue is too intact to gently pull apart, use surgical scissors to cut the heart into 4-6 pieces before proceeding with the digestion in 50 mL tubes.

Resource availability

Lead contact

Alexander Pinto, alex.pinto@baker.edu.au

Materials availability

This study did not generate new unique reagents.
REAGENT or RESOURCESOURCEIDENTIFIER
Chemicals, peptides, and recombinant proteins

Collagenase Type IIWorthington Biochemical CorporationLS004179
Collagenase Type IVWorthington Biochemical CorporationLS004188
Protease Type XIVSigma AldrichP5147
DPBS, no calcium, no magnesiumGibco™14190-250
UltraPure™ DNase/RNase-Free MQH2OInvitrogen™10977015
NaClSigma-AldrichS7653
GlucoseSigma-AldrichG8270
EDTASigma-AldrichEDS
TaurineSigma-AldrichT0625
BDMSigma-AldrichB0753
(optional: Blebbistatin in lieu of BDM)Sigma-AldrichB0560
NaH2PO4Sigma-Aldrich71496
HEPESSigma-Aldrich54457
KClSigma-AldrichP9541
MgCl2Sigma-Aldrich208337
FBSGibco™10099141
HBSSGibco™14185052
CaCl2Sigma-AldrichC5670
80% v/v EthanolAnyAny
Laminin Mouse Protein, NaturalGibco™23017015
MEM, Hanks' Balanced SaltsGibco™11575032
Insulin-Transferrin-Selenium-Sodium Pyruvate (ITS-A) (100X)Gibco™51300044
Insulin, Neutral, 1000units/10mL vialNovo NordiskActrapid
CD lipid concentrateThermo Fisher11905031
Magnesium sulfateSigma-AldrichM7506
Sodium pyruvateSigma-AldrichP2256
Sodium bicarbonateSigma-AldrichS5761
L-Glutamic acid monosodium salt hydrateSigma-AldrichG5889
Sodium acetateSigma-AldrichS2889
Phenol red sodium saltSigma-AldrichP5530
Penicillin-Streptomycin (10,000 U/mL)Gibco™15140-122
Bovine serum albumin (BSA)Sigma-AldrichA9418

Experimental models: Organisms/strains

12- to 16-week-old male C57BL6The Jackson Laboratory000664

Other

Allegra X-15R refrigerated swing bucket centrifuge (or equivalent)Beckman Coulter4882960
Water bath, 37°CAnyAny
L/S Digital Pump System with Easy-Load II Pump Head (or equivalent)MasterflexHV-77921-70
L/S® Precision Pump Tubing, Tygon® E-LFL, L/S 13MasterflexHV-06440-13
25GX5/8 Needles (or equivalent)Terumo19005-TE
30GX1/2 Needles (or equivalent)Terumo19050-TE
10 mL Luer Lock Syringes (or equivalent)Terumo19046-TE
Graefe Forceps - Curved/Serrated, 0.8 × 0.7 mm, Stainless SteelFine Science Tools11051-10
Walton Scissors - Curved/Sharp, 15 mm, 9.5 cm, Stainless SteelFine Science Tools14077-09
Three-way stopcocksBecton Dickinson394600
Luer Assortment KitCole-Parmer45511-00
Neodymium magnet blocks (L: 12.5 mm, W: 6 mm, H: 3.5 mm, Grade 43-46 MGOe)Alpha Magnetics Pty LtdN45
PETG 3D printing materialPrusa ResearchPRM-PETG-URB-1000
3D printerPrusa ResearchOriginal PRUSA i3 MK3S
Curved hemostatAnyAny
Solid-core 22AWG electrical wireAdafruit Industries289
Masterflex Tygon TubingCole-Parmer06419-03
Magnetic baking trayAnyAny
Nylon mesh 177 μm (for cardiomyocytes)Note: While we use nylon mesh with a pore size of 177 μm, we recommend mesh with pore sizes ranging from 170 μm to 250 μm for cardiomyocyte isolations.Fresh By DesignNM177
3 mL Pasteur pipettes, sterileAnyAny
50 mL Tubes, conical baseCorning352070
70 μm Nylon mesh (for non-myocytes)AnyAny
15 mL Tubes, conical baseFalcon™352096
60 mm Tissue culture dishFalcon™353002
14 mL Polypropylene Round Bottom TubeFalcon™352059
Sterile 70 mL specimen jarsSARSTEDT75.9922.730
3D object file (STL) for hemostat holderhttps://github.com/pinto-lab/Farrugia-et-al_2021-magnetic-hemostat-holder

100 × collagenases II and IV

ReagentFinal concentrationAmount
Collagenase II50 mg/mL1 g
Collagenase IV50 mg/mL1 g
ddH2On/a20 mL
Totaln/a20 mL

Reconstitute both collagenases in ddH2O. Filter sterilize through 0.22 μm and store in 1 mL aliquots in -80°C. Stable for up to 6 months.

1000 × protease XIV

ReagentFinal concentrationAmount
Protease XIV50 mg/mL1 g
ddH2On/a20 mL
Totaln/a20 mL

Reconstitute in ddH2O. Filter sterilize through 0.22 μm and store in 200 μL aliquots in -80°C. Stable for up to 6 months.

EDTA buffer

ReagentFinal concentrationAmount
NaCl130 mM0.379 g
KCl5 mM19.6 mg
NaH2PO40.5 mM3 mg
HEPES10 mM119 mg
Glucose10 mM90.1 mg
BDM10 mM50.6 mg
(or blebbistatin)5 mM73.1 mg
Taurine10 mM62.6 mg
EDTA5 mM73.1 mg
ddH2On/a50 mL
Totaln/a50 mL

Prepare 50 mL per heart. Prepare required volume of solution in ddH2O with a final pH of 7.8. Filter sterilize through 0.22 μm and protect from light. Store at 4°C for up to 1 week.

Perfusion buffer

ReagentFinal concentrationAmount
NaCl130 mM0.456 g
KCl5 mM22.4 mg
NaH2PO40.5 mM3.6 mg
HEPES10 mM0.143 g
Glucose10 mM0.108 g
BDM10 mM60.7 mg
(or blebbistatin)5 mM87.7 mg
Taurine10 mM75.1 mg
MgCl21 mM5.71 mg
ddH2On/a60 mL
Totaln/a60 mL

Prepare 60 mL per heart. Prepare required volume of solution in MQH2O with a final pH of 7.8. Filter sterilize through 0.22 μm and protect from light. Store at 4°C for up to 1 week.

Wash buffer

ReagentFinal concentrationAmount
CaCl2 (1M)0.9 mM90 μL
DPBSn/a9.91 mL
Totaln/a10 mL

Prepare 10 mL per heart. Keep sterile and store at 4°C until experiment day. Can be made on or prior to experiment day.

10 × ACM

ReagentFinal concentrationAmount
KCl54 mM0.403 g
MgSO435 mM0.421 g
Na pyruvate500 mM5.502 g
NaHCO3200 mM1.680 g
Glucose110 mM1.982 g
HEPES200 mM4.766 g
Na glutamate235 mM3.974 g
Na acetate48.7 mM0.399 g
EDTA1 mM29.2 mg
Phenol red2 mg/mL0.2 g
ddH2O80 mL
Totaln/a80 mL

Prepare in 80 mL MQH2O (final volume 100 mL). Adjust pH to 7.25 with 1M NaOH, taking note of volume required. Add NaCl calculated by the following equation:

NaCl to add (g) = -0.0585 × (volume of NaOH added) + 6.02

Make up to 100 mL with MQH2O. Filter sterilize through 0.22 μm. Can be prepared 3–4 days in advance and stored at 4°C.

Perfusion buffer with enzymes

ReagentFinal concentrationAmount
100 × Collagenase II and IV1 ×400 μL
1000 × Protease XIV1 ×40 μL
Perfusion Buffern/a40 mL
Totaln/a40.440 mL

Prepare from cold reagents 40 mL per heart on day of experiment and allow to warm to room temperature.

Stop buffer

ReagentFinal concentrationAmount
Fetal calf serum5%1 mL
Perfusion buffern/a19 mL
Totaln/a20 mL

Prepare 20 mL per heart on day of experiment.

ACMBICT

ReagentFinal concentrationAmount
BDM1.01 mg/mL50.5 mg
Creatine0.657 mg/m32.85 mg
Taurine3.75 mg/mL187.5 mg
Insulin0.1 IU/mL5 IU
10 × ACM1 × ACM5 mL
ddH2On/a45 mL
Totaln/a50 mL

Prepare 50 mL per heart. Keep at RT

ACMBICT/FCS

ReagentFinal concentrationAmount
Fetal calf serum10%3 mL
ACMBICTn/a27 mL
Totaln/a30 mL

Prepare 30 mL per heart. Keep at RT

Modified MEM

ReagentFinal concentrationAmount
Fetal calf serum10%3 mL
BDM1 mg/mL30 mg
MEMn/a27 mL
Totaln/a30 mL

Prepare 30 mL per heart. Keep at RT

Myocyte wash buffer 1

ReagentFinal concentrationAmount
ACMBICT/FCSn/a9 mL
Modified MEM0.18 mM Ca2+1 mL
Totaln/a10 mL

Prepare 10 mL per heart and store at RT until use.

Myocyte wash buffer 2

ReagentFinal concentrationAmount
ACMBICT/FCSn/a6 mL
Modified MEM0.45 mM Ca2+2 mL
Totaln/a8 mL

Prepare 8 mL per heart and store at RT until use.

Myocyte wash buffer 3

ReagentFinal concentrationAmount
ACMBICT/FCSn/a4 mL
Modified MEM1.08 mM Ca2+6 mL
Totaln/a10 mL

Prepare 10 mL per heart and store at RT until use.

Plating media

ReagentFinal concentrationAmount
FCS10%2 mL
BDM1 mg/mL20 mg
Penicillin/streptomycin1 ×200 μL
MEMn/a17.8 mL
Totaln/a20 mL

Prepare 20 mL per heart. Incubate at 37°C, 5% CO2 with loosened cap until use.

Maintenance media

ReagentFinal concentrationAmount
BSA0.5%100 mg
ITS-A1 ×200 μL
CD lipid concentrate1 ×200 μL
Penicillin/streptomycin1 ×200 μL
MEMn/a19.4 mL
Totaln/a20 mL

Prepare 20 mL per heart and filter sterilize. Incubate at 37°C, 5% CO2 with loosened cap until use.

  5 in total

1.  Isolation and analysis of single cells from the mouse heart.

Authors:  Alexander R Pinto; Anjana Chandran; Nadia A Rosenthal; James W Godwin
Journal:  J Immunol Methods       Date:  2013-04-09       Impact factor: 2.303

2.  Revisiting Cardiac Cellular Composition.

Authors:  Alexander R Pinto; Alexei Ilinykh; Malina J Ivey; Jill T Kuwabara; Michelle L D'Antoni; Ryan Debuque; Anjana Chandran; Lina Wang; Komal Arora; Nadia A Rosenthal; Michelle D Tallquist
Journal:  Circ Res       Date:  2015-12-03       Impact factor: 17.367

3.  Cardiac cellularity is dependent upon biological sex and is regulated by gonadal hormones.

Authors:  Galen T Squiers; Micheal A McLellan; Alexei Ilinykh; Jane Branca; Nadia A Rosenthal; Alexander R Pinto
Journal:  Cardiovasc Res       Date:  2021-08-29       Impact factor: 13.081

4.  A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Nonmyocytes From the Adult Mouse Heart.

Authors:  Matthew Ackers-Johnson; Peter Yiqing Li; Andrew P Holmes; Sian-Marie O'Brien; Davor Pavlovic; Roger S Foo
Journal:  Circ Res       Date:  2016-08-08       Impact factor: 17.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.